MX2015000618A - Derivados de di- y tri-heteroarilo como inhibidores de la agregacion de proteinas. - Google Patents

Derivados de di- y tri-heteroarilo como inhibidores de la agregacion de proteinas.

Info

Publication number
MX2015000618A
MX2015000618A MX2015000618A MX2015000618A MX2015000618A MX 2015000618 A MX2015000618 A MX 2015000618A MX 2015000618 A MX2015000618 A MX 2015000618A MX 2015000618 A MX2015000618 A MX 2015000618A MX 2015000618 A MX2015000618 A MX 2015000618A
Authority
MX
Mexico
Prior art keywords
protein aggregation
tri
inhibitors
heteroaryl derivatives
methods
Prior art date
Application number
MX2015000618A
Other languages
English (en)
Spanish (es)
Inventor
Wolfgang Wrasidlo
Original Assignee
Neuropore Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuropore Therapies Inc filed Critical Neuropore Therapies Inc
Publication of MX2015000618A publication Critical patent/MX2015000618A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2015000618A 2012-07-16 2013-07-16 Derivados de di- y tri-heteroarilo como inhibidores de la agregacion de proteinas. MX2015000618A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261672239P 2012-07-16 2012-07-16
PCT/US2013/050719 WO2014014937A1 (en) 2012-07-16 2013-07-16 Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation

Publications (1)

Publication Number Publication Date
MX2015000618A true MX2015000618A (es) 2015-04-10

Family

ID=49949212

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000618A MX2015000618A (es) 2012-07-16 2013-07-16 Derivados de di- y tri-heteroarilo como inhibidores de la agregacion de proteinas.

Country Status (15)

Country Link
US (1) US9284309B2 (enExample)
EP (1) EP2872143B1 (enExample)
JP (1) JP2015522617A (enExample)
KR (1) KR20150031481A (enExample)
CN (1) CN104703604A (enExample)
AU (1) AU2013290361A1 (enExample)
BR (1) BR112015001096A2 (enExample)
CA (1) CA2877983A1 (enExample)
ES (1) ES2661394T3 (enExample)
HK (1) HK1210598A1 (enExample)
IL (1) IL236712A0 (enExample)
IN (1) IN2015DN01171A (enExample)
MX (1) MX2015000618A (enExample)
RU (1) RU2015104962A (enExample)
WO (1) WO2014014937A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ722487A (en) 2014-01-29 2022-04-29 Ucb Biopharma Sprl Heteroaryl amides as inhibitors of protein aggregation
EP3328379B1 (en) 2015-07-29 2021-07-28 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
JP7073385B2 (ja) 2017-01-26 2022-05-23 ユーシービー バイオファルマ エスアールエル タンパク質凝集のモジュレーターとしての二環式ビス-ヘテロアリール誘導体
RU2019126170A (ru) * 2017-01-26 2021-02-26 Юсб Байофарма Спрл Бисгетероарильные производные в качестве модуляторов агрегации белков
EP3573981B1 (en) * 2017-01-26 2022-03-16 UCB Biopharma SRL Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation
US20190382346A1 (en) 2017-02-28 2019-12-19 Universitat Autonoma De Barcelona (nitro-phenyl)-nitropyridine compounds for treating synucleinopathies
WO2019025424A1 (en) 2017-08-04 2019-02-07 Universitat Autonoma De Barcelona COMPOUNDS FOR TREATING SYNUCLEINOPATHIES
WO2019161917A1 (en) 2018-02-23 2019-08-29 Universitat Autonoma De Barcelona 4-substituted 1-ethenylsulfonyl-2-nitrobenzene compounds for treating synucleinopathies
CN113683598B (zh) * 2020-05-18 2022-10-14 成都先导药物开发股份有限公司 一种免疫调节剂
WO2025223458A1 (zh) * 2024-04-23 2025-10-30 深圳众格生物科技有限公司 一种cyp11a1抑制剂、其制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU782878B2 (en) 2000-02-05 2005-09-08 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
JP4052573B2 (ja) 2000-09-15 2008-02-27 バーテックス ファーマシューティカルズ インコーポレイテッド イソオキサゾールおよびerkのインヒビターとしてのその使用
AU2003257094A1 (en) * 2002-08-08 2004-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
AU2010243613B2 (en) * 2009-04-30 2015-05-07 Glaxo Group Limited Oxazole substituted indazoles as PI3-kinase inhibitors
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
JP5922031B2 (ja) * 2009-12-16 2016-05-24 ニューロポア セラピーズ,インコーポレイティド 化合物
US9198891B2 (en) 2010-05-21 2015-12-01 New York University Method of treating cancer by inhibition of protein kinase-like endoplasmic reticulum protein kinase

Also Published As

Publication number Publication date
IL236712A0 (en) 2015-02-26
EP2872143A4 (en) 2015-12-02
HK1210598A1 (en) 2016-04-29
EP2872143A1 (en) 2015-05-20
ES2661394T3 (es) 2018-03-28
EP2872143B1 (en) 2017-12-13
BR112015001096A2 (pt) 2017-06-27
US20150183776A1 (en) 2015-07-02
AU2013290361A1 (en) 2015-02-05
JP2015522617A (ja) 2015-08-06
US9284309B2 (en) 2016-03-15
WO2014014937A1 (en) 2014-01-23
CN104703604A (zh) 2015-06-10
KR20150031481A (ko) 2015-03-24
IN2015DN01171A (enExample) 2015-06-26
CA2877983A1 (en) 2014-01-23
RU2015104962A (ru) 2016-09-10

Similar Documents

Publication Publication Date Title
MX2015000618A (es) Derivados de di- y tri-heteroarilo como inhibidores de la agregacion de proteinas.
PH12016501493A1 (en) Heteroaryl amides as inhibitors of protein aggregation
PH12015500983A1 (en) Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
PH12015500724B1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
MX370792B (es) Composiciones para usarse en el tratamiento de cáncer.
MX2019008256A (es) Derivados de bis-heteroarilo biciclicos como moduladores de agregacion de proteinas.
MX2019007053A (es) Derivados de bis-heteroarilo como moduladores de la agregacion de proteinas.
MX369952B (es) Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de transcripción de choque térmico 1.
IN2014MN02056A (enExample)
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2018004109A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
HK1202452A1 (en) Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
AU2012280776B2 (en) Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
MX2019007054A (es) Derivados de alcoxi bis-heteroarilo como moduladores de la agregacion de proteinas.
JO3483B1 (ar) 4-هيدروكسي -2- مثيل -5- (بروبان-2-يليدين) هكس - 3- ين حلقي كربالدهيد للوقاية من ومعالجة مرض معرفي أو تنكسي عصبي أو عصبي
IN2014DN08443A (enExample)
MX2016004094A (es) Composicion farmaceutica que comprende capecitabina y ciclofosfamida.
EP3881845A3 (en) Combination of trazodone and gabapentin for the treatment of pain
MX377759B (es) Actividad antimicrobiana "in vitro" de la combinacion de peptidos antibiocidas de alacran con antibioticos de uso comun.